Amgen is conducting a Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of XXXXXXXXXXX in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #20210145

Incyte is conducting a Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXXXXXX in Participants with Moderate to Severe Hidradenitis Suppurativa

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #  INCB- 54707-301

Acrotech is conducting an Open-label Study to Assess the Long-Term Safety of XXXXXXXX Ointment in Mild to Moderate Atopic Dermatitis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # MEDI-MM36-302

Eli Lilly is conducting a US-Based Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab (Taltz)

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #  I1F-MC-B018

Eli Lilly is conducting an Open-Label Study of XXXXXXXXXX in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # J2T-MC-KGBP

Trial – AMGEN/IQVIA

Suffering from Chronic Hives?

A 32-week Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of xxxxxxxxxx for the Treatment of Chronic Spontaneous Urticaria

Males and Females between the ages of 18-80 may qualify.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # 20190194

Eli Lilly and Company are conducting a Long-term Study to Assess the Safety and Efficacy of xxxxxxxxxxx in Patients With Moderate-to-Severe Atopic Dermatitis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # J2T-DM-KGAA/DRM06-AD07

Trial – Sun Pharma | IQVIA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of XXXXXXXXX in the Treatment of Moderate to Severe Nail Psoriasis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #TILD-18-19

Trial – Amgen | PPD

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXXXXX (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #